Development and Validation of a Novel Geriatric Risk Score for Prognostication in Older Patients With Hodgkin Lymphoma: A Multicenter Retrospective Study
Open Access
- 13 August 2026
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 101 (S3) , 50-64
Abstract
Outcomes in older patients with Hodgkin lymphoma (HL) are compromised by the interplay of patient frailty and disease aggressiveness; however, current stratification tools, including the International Prognostic Score (IPS) and Comprehensive Geriatric Assessment (CGA), lack sufficient prognostic discrimination in the older HL population. We developed and validated a prognostic model integrating metabolic tumor burden and geriatric assessment. In this retrospective study across 14 centers in China between 2006 and 2024, we enrolled 306 patients aged ≥ 60 years with histologically confirmed HL. Patients were randomly partitioned into training ( n = 250) and validation ( n = 56) cohorts. Among the 306 patients, 98 deaths and 130 progression events were recorded during follow‐up. We analyzed 21 candidate variables. The least absolute shrinkage and selection operator (LASSO) analysis and multivariable Cox regression identified five independent predictors for 5‐year overall survival (OS): age > 73 years, baseline 18F‐FDG PET/CT‐derived total lesion glycolysis (TLG) > 200, hemoglobin ≤ 101 g/L, activities of daily living (ADL) dependence, and lymphocyte‐depleted classical Hodgkin lymphoma (LDCHL). A weighted Geriatric Risk Score stratified patients into low‐, intermediate‐, and high‐risk groups. In the validation cohort, the Geriatric Risk Score showed higher discriminatory accuracy than the CGA for both OS (C‐index, 0.770 [95% CI, 0.674–0.867] vs. 0.671 [0.581–0.762]) and PFS (0.761 [0.668–0.853] vs. 0.635 [0.535–0.735]). Among advanced‐stage (Ann Arbor stage III–IV) patients, it also outperformed the IPS‐7 and IPS‐3. By integrating metabolic tumor burden and geriatric assessment, the Geriatric Risk Score improves risk stratification over existing tools in older patients with HL.Keywords
This publication has 25 references indexed in Scilit:
- External validation and calibration of the HoLISTIC Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the Brazilian Hodgkin lymphoma registryBritish Journal of Haematology, 2024
- Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2024
- A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and raceBritish Journal of Haematology, 2022
- PET/CT in Hodgkin Lymphoma: An UpdateSeminars in Nuclear Medicine, 2022
- Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapyJournal of Geriatric Oncology, 2021
- Real‐world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000–2014, focusing on patients aged >60 yearseJHaem, 2021
- Comorbidity assessment to determine prognosis in older adult patients with classical Hodgkin lymphomaHematological Oncology, 2020
- Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern eraBritish Journal of Haematology, 2015
- Presentation of multivariate data for clinical use: The Framingham Study risk score functionsStatistics in Medicine, 2004
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998